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YOUNG INVESTIGATOR PERSPECTIVES
The Role of Leptin in the Regulation of
Energy Balance and Adiposity
Gertjan van Dijk
Department of Animal Physiology, Division Neuroendocrinology, School of Behavioural and Cognitive Neurosciences,
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Abstract
Since its discovery, leptin (a 167-amino acid product of the OB gene) has quickly moved to the
forefront as an important hormone for regulation of energy balance. It closes a feedback loop from
adipose tissue to hypothalamic neuropeptide-containing neural circuitry involved in regulation of food
intake and neuroendocrine/autonomic outflow. While increased central leptin signalling reduces
adiposity via a reduction in food intake, it also has remarkable metabolic effects that promote
leanness, independent of food intake. These include: (i) increased energy expenditure, (ii) in-place
degradation of fat, and (iii) increased thermogenesis. Hypothalamic neurones that synthesize
corticotropin releasing hormone and melanocortins (i.e. a-melanocyte-stimulating hormone and
agouti-related protein) are likely effector pathways that mediate the anorexigenic and metabolic
effects of leptin. Activation of sympathetic outflow (via neuropeptidergic effector pathways of central
leptin) to a number of tissues that store fat might be an important mechanism through which these
peripheral metabolic effects are elicited. It is proposed that these peripheral metabolic effects
contribute to the satiating properties of leptin.
Introduction
In adulthood, higher animals including rodents and primates
have a substantial amount of fat in their bodies (between 10%
and 15%), mostly stored in white adipose tissue (WAT). An
important function of fat is to buffer digested nutrients in the
form of triglycerides. After hydrolysis of triglycerides into free
fatty acids (FFA) and glycerol, FFA can be used as fuel for
oxidative phosphorylation, which provides the basic source of
energy (i.e. ATP). The amount of energy stored in the form of
triglycerides and potentially employable for metabolic pur-
poses is enormous compared to that of glycogen, another
important fuel depot in the body. If no such fat store were
available, intake from the environment would have to be con-
tinuous. This is obviously not the case because food intake
occurs mostly in specific bouts (i.e. meals) that are interspaced
by relatively long time intervals. Thus, controlled hydrolysis
and oxidative phosphorylation allows continuous energy
expenditure (i.e. during and between meals and even
under conditions of prolonged starvation) needed for
muscular movement, reproduction, growth, cellular main-
tenance and for keeping body temperature in the optimal
physiological range.
An intriguing fact about fat is that many individuals have a
constant amount of it in their bodies over most of their
lifespan. One implication of this is that the amount of tri-
glycerides utilized for metabolic purposes is exactly met by
the synthesis of triglycerides from fuels directly or indirectly
derived from ingested nutrients. Over the past few years,
evidence has accumulated that the obesity (OB) gene, a highly
conserved DNA region in many species (in humans and mice
found on chromosome 6 and 7, respectively) plays a crucial
role in the match between triglyceride depletion and storage.
The OB gene encodes a highly conserved 4.5 kb adipose tissue
messenger which is translated into the 167-amino acid pro-
duct, leptin. Whereas leptin is able to regulate triglyceride
storage via a paracrine action (1, 2), the present review focuses
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on the interaction of leptin with the central nervous system
(CNS). This feedback of leptin on CNS circuitry is suggested
to control energy balance and body adiposity via adaptations
in both food intake and food intake-independent mechanisms
in a coordinated fashion.
The concept of leptin action in the CNS
Several decades ago, Kennedy recognized the stability of body
adiposity and energy balance (3). At that time, it was already
known from the pioneering work of Hetherington and
Ranson that electrolytic lesioning of the ventrobasal hypo-
thalamus including the arcuate (Arc), dorsomedial (DMH)
and ventromedial (VMH) nuclei causes rats to become drama-
tically hyperphagic and obese (4). Based on these data,
Kennedy proposed the idea that there is a factor proportional
to the size of body fat stores that signals to the hypothalamus
(3). Changes in this fat signal would lead to appropriate
changes in food intake to maintain body adiposity level.
Evidence that regulation of adiposity involves a hormonal
feedback signal in the body has been obtained from experi-
ments with parabiotic rats. These are surgically united pairs of
rats which permanently exchange blood through a capillary
anastomosis. If one rat is made obese by a lesion in the
ventrobasal hypothalamus, the other becomes very thin, ap-
parently through reducing its food intake and increasing
energy expenditure in response to the obesity in the partner,
with which it shares a blood supply (5). Several candidate
lipostat factors (e.g. insulin, steroids) have been hypothesized
throughout the years, but it was the discovery of leptin
by Zhang et al. in 1994 (6) that significantly reinforced
Kennedy’s concept.
Leptin mRNA levels in adipocytes and the concentration
of plasma leptin change rapidly over the diurnal cycle and
may reflect rapid changes in energy balance associated with
fasting and refeeding (7). Accordingly, a fall in plasma leptin
has been suggested to signal starvation (8). In the longer
term, however, the integrated level of plasma leptin reflects
body adiposity. While a number of hormones (e.g. insulin,
corticosterone) are involved in the synthesis of leptin, the
principal determinant of leptin production has yet to be dis-
covered. Among the tissues that express mRNA encoding the
signalling form of the leptin receptor (OB-Rb; among five
splice variants, the only form known to activate transcription
factors) are several peripheral tissues and organs (e.g. adipose
tissue, liver, muscle) and a number of regions in the CNS,
including the ventrobasal (i.e. Arc, VMH, DMH) hypo-
thalamus (8). The role of leptin and its receptors in regulation
of energy balance is well-illustrated by observations that
rodents that have mutations in either their signalling
leptin receptors [i.e. db/db mice or fa/fa Zucker rats (9)] or
in leptin production [i.e. ob/ob mice (10)] are extremely obese.
Apparently, these animals lack a negative feedback signal
from their adipose tissue stores to the CNS, which would be
necessary to allow appropriate adjustments to disturbances
(i.e. obesity) in adipose tissue mass. Recombinant functional
leptin administration obviously only reverses obesity in
animals that synthesize a deficient form of leptin, but not
in animals with a deficient leptin receptor (9, 10). Although
extremely rare, mutations in leptin synthesis leading to morbid
obesity have also been reported in humans; for a review, see
(11). The role of leptin in regulation of adiposity of animals
without defects in leptin synthesis or signalling has primarily
been investigated in rodents. As an example, Koyama et al.
(12) showed that normal lean rats lose virtually all fat when
these animals undergo adenovirus gene transfer of the OB
gene. This treatment, however, is not effective in animals
with an electrolytic lesion in the ventrobasal hypothalamus,
demonstrating the importance of this brain region in
mediating the effects of leptin on energy balance (12).
An effective way to reduce body fat is through a reduction
in food intake, and there are many studies that consistently
demonstrate the anorexigenic efficacy of leptin (8, 11, 13).
Of importance for considering the specificity of leptin as a
putative anorexigenic hormone is our observation that leptin
effects on food intake are not due to incapacitation or induc-
tion of malaise (14). Furthermore, relatively low doses of
leptin delivered into the third cerebral ventricle (i3vt) of rats
(9) and mice (10), and even lower doses in the VMH and
Arc (15), are much more potent to reduce food intake
than when leptin is delivered peripherally. This indicates that
the VMH/Arc region is the target where leptin acts. Other
evidence pointing in this direction are findings that i3vt (16)
and intravenous (13) administration of anorexigenic doses
of leptin increases labelling of c-Fos (a marker for neuronal
activity) in several hypothalamic regions including the
ventrobasal hypothalamus.
Effects of leptin in the CNS on substrate metabolism
and fuel handling
In addition to being hyperphagic, leptin-deficient rodents
utilize dietary energy more efficiently than wild-type animals
(17), which suggests effects of leptin on body adiposity inde-
pendent of food intake. The findings that leptin treatment of
ob/ob mice is able to increase oxygen consumption in these
animals, and induces leanness more potently than is expected
based on the reduction in food intake alone (18), may imply
that brain leptin has profound metabolic effects. Three aspects
of central leptin effects on adiposity that are independent of
food intake are described below.
Energy expenditure
In a recent study, we have investigated the central effect of
leptin on energy balance and body adiposity in genetically
normal rats independent of leptin effects on food intake (19).
Briefly, rats were treated i3vt with leptin (3 mg/day) or with
synthetic cerebrospinal fluid (sCSF, the vehicle in which leptin
was dissolved) over a 3-day period during which animals ate
approximately 50% of the amount eaten by sCSF-treated, ad
libitum fed controls. These anorexigenic effects by itself
have major consequences for metabolism and energy expen-
diture. Therefore, an additional group of animals received the
vehicle, but was pair-fed to the i3vt leptin-treated group, and
thus served to investigate the effect of leptin on metabolism
independent of the effect of leptin on food intake. On the last
day of treatment, animals were put into an indirect calori-
metry chamber for a 3-h recording of carbohydrate oxidation
(CHO-ox), fat oxidation (Fat-ox) and energy expenditure
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(EE), during which the animals were not allowed to eat.
Meanwhile, behaviour of these animals was videotaped so
that the measurement of CHO-ox, Fat-ox and EE could be
related to when the animals were under resting conditions.
It was observed that i3vt leptin-treated animals, while eating
only approximately 50% of the food that was eaten by the
ad libitum controls, had a level of EE that was indistinguish-
able from ad libitum controls during the resting phase. In
contrast, the pair-fed controls had a significantly lower level of
EE relative to both other groups during the resting phase.
Since there were no differences in time spent on resting,
grooming and alertness among treatment groups, these data
can be interpreted to indicate that the fall in resting EE that is
normally associated with reduced caloric intake is prevented
by i3vt leptin treatment. Consistent with these effects was
the observation that i3vt leptin-treated animals were leaner
than their pair-fed controls at the end of treatment. Body
fat analysis and energy expenditure are depicted in Fig. 1.
With respect to the specific utilization of carbohydrate and
fat, only the pair-fed group, but not the leptin-treated group,
had a significantly lower CHO-ox relative to ad libitum
controls, whereas the level of Fat-ox was only significantly
increased in the leptin-treated, but not in the pair-fed group,
relative to the ad libitum controls. Thus, these data indicate
that the relative high EE in leptin-treated animals versus that
of pair-fed animals occurred at the expense of both fat as well
as carbohydrate (Fig. 2).
In-place utilization of fat
In addition to the lower resting EE, pair-fed animals had
elevated levels of plasma FFA, ketones, and glycerol
compared to ad libitum controls, and these are considered
normal responses to food restriction where triglyceride
breakdown, ketone body production and b-oxidation
predominate. In contrast, the concentration of plasma FFA
and ketones of i3vt leptin-treated animals was at the level of
ad libitum controls. Because the plasma level of glycerol was
elevated to a similar extent in leptin-treated and pair-fed
animals, leptin apparently did not prevent the intracellular
breakdown of triglycerides (Fig. 3). In fact, lipid depletion and
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FIG. 1. The percentage of body adiposity and resting energy expenditure
of ad libitum feeding male Wistar rats that received daily intracerebro-
ventricular infusion of synthetic cerebrospinal fluid (sCSF, open bars;
n=8) or 3.5 mg leptin (filled bars; n=8). An additional group of rats
received intracerebroventricular infusion of sCSF and were pair-fed to
leptin-treated animals (shaded bars; n=8). Statistical significance between
ad libitum/sCSF-treated and other groups; *P<0.05. Statistical signifi-


















FIG. 2. Carbohydrate oxidation (CHO-ox) and Fat oxidation (Fat-ox) of
ad libitum feeding male Wistar rats that received daily intracerebro-
ventricular infusion of synthetic cerebrospinal fluid (sCSF, open bars;
n=8) or 3.5 mg leptin (filled bars; n=8). An additional group of rats
received intracerebroventricular infusion of sCSF and were pair-fed to
leptin-treated animals (shaded bars; n=8). CHO-ox and Fat-ox were
determined using indirect calorimetry over a 3-h period on the last day of
treatment. Statistical significance between ad libitum/sCSF-treated and



























FIG. 3. Plasma concentrations of ketones, free fatty acids (FFA), and
glycerol of ad libitum-feeding male Wistar rats that received daily intra-
cerebroventricular infusion of synthetic cerebrospinal fluid (sCSF, open
bars; n=8) or 3.5 mg leptin (filled bars; n=8). An additional group of rats
received intracerebroventricular infusion of sCSF and were pair-fed to
leptin treated animals (shaded bars; n=8). Statistical significance between
ad libitum/sCSF-treated and other groups; *P<0.05 and **P<0.01.
Statistical significance between leptin and pair-fed group: ††P<0.01.
Adapted from (19) with permission.
Leptin regulation of energy balance and adiposity 915
# 2001 Blackwell Science Ltd, Journal of Neuroendocrinology, 13, 913–921
as judged from the analysis of body fat and indirect
calorimetry depicted in Figs 1 and 2, respectively. One
possible interpretation pertinent to the outcome of these
results might be that central leptin stimulates lipolysis and
concomitantly increases FFA uptake from the blood stream
into metabolically active tissue which, in turn, leads to a
reduction in plasma FFA levels. However, increased uptake
of FFA into the liver would most certainly lead to a rise in
plasma level of ketone bodies in leptin-treated animals, and
that is not what happened. The second interpretation might be
that central leptin stimulates lipolysis while at the same time
reducing FFA release from adipocytes. In turn, increased
intracellular FFA availability inside adipocytes as well as other
tissues that store fat (e.g. muscle, liver, pancreas) could serve
as a fuel for increased b-oxidation (i.e. in-place utilization)
within the same cells. Thus, rather than increasing the export
of FFA to other tissues, these data suggest that leptin acts on
CNS pathways that stimulate intracellular triglyceride meta-
bolism in white adipose tissue (and perhaps other tissues that
store fat). The reduction in plasma ketone levels by central
leptin treatment was probably secondary to the reduced avail-
ability of FFA to the liver where increased FFA availability
would normally result in increased ketogenesis.
The effects of leptin administration on circulating fat
fuels mentioned above confirm and extend the findings of
Shimabukuro et al. (2), who, using rats made hyperleptinemic
by adenovirus gene transfer, found evidence for a mechanism
in which leptin increases intracellular fat oxidation in tissues
(i.e. in-place utilization) such that lipolysis proceeds without
increased levels of plasma FFA and ketones. Whereas it has
been proposed that this occurs via a direct action of leptin in
peripheral tissues (1, 2), the results from our studies demon-
strate that these metabolic responses can be mediated via an
action in the CNS. One mechanism to facilitate breakdown
of triglycerides is through stimulation of the sympathetic
nervous system (SNS) (20). Although the significance of
sympathetic innervation of WAT has been questioned for
many years, recent work by Bartness et al. has led to true
neuroanatomical evidence for the origins of sympathetic
nervous system outflow from the CNS to WAT (21). They
injected a retrograde transsynaptic tracer (pseudorabies virus)
in WAT of Siberian hamsters and observed labelling in a
number of CNS regions including the intermediolateral cell
column of the spinal cord and in the paraventricular nucleus
of the hypothalamus (PVN). Since leptin administration into
the CNS stimulates regional sympathetic nerve traffic to a
number of organs (22) and causes an increase in the circulating
level of norepinephrine (23), it might be hypothesized that
leptin stimulates SNS outflow to WAT. This idea is consistent
with the finding of Commins et al. who found that leptin
administration lowered its own expression in WAT, provided
the sympathetic nervous system remained intact (24).
Thermogenesis
In addition to being severely obese, rodents with a deficient
leptin system (e.g. ob/ob mice) have lower body temperatures
in conditions of room (i.e. 20–22uC) temperature and are
not capable of maintaining their body temperature when
subjected to a cold environment (25). These observations
suggest that leptin is involved in production of body heat. A
well-known mechanism to increase thermogenesis is to render
metabolism less efficient such that part of the energy derived
from food is released as heat rather than in the form of
ATP. In 1985, Klingenberg and Winkler discovered that the
mitochondria of brown adipose tissue (BAT) are metabo-
lically inefficient because of the presence of uncoupling pro-
tein (UCP) in the inner mitochondrial wall (26). Activation of
UCP disrupts the electrochemical gradient (necessary to drive
ATP production) due to the fact that UCP transports protons
across, thereby transmitting heat. Subsequently, it was found
that UCP activity in BAT adipocytes is stimulated by cold,
increased SNS tone, and by leptin (27). Collins et al. have
shown that leptin signalling in the CNS is able to increase
BAT UCP synthesis, and SNS innervation of BAT is required
for this effect (28).
The contribution of BAT UCP in the generation of total
body heat has long been debated since BAT is present in only
very small amounts in adult animals (27, 29). Thus, the failing
interaction of leptin with BAT UCP would hardly, if at
all, provide an explanation for the hypothermia observed
in leptin-deficient animals. In recent years, however, other
subtypes of UCP have been cloned and found in almost any
other tissue involved in regulation of energy balance. In
particular UCP2 and UCP3 are of interest since, besides being
present in BAT, these subtypes are found in WAT, muscle and
in the liver (27). The work of Cusin et al. provided a functional
link between central leptin action and whole body UCP
activity in rats (30). These researchers demonstrated that CNS
leptin administration (12 mg/day into the lateral ventricle
during a 4-day period) was able to stimulate BAT UCP
(referred to as UCP1), UCP2 and UCP3 in BAT, WAT,
muscle and liver, respectively, relative to animals that were
pair-fed to the leptin-treated group (30). In our hands, this
treatment significantly increased body temperature indepen-
dent of locomotor activity, which is consistent with leptin
stimulation of UCP activity (Fig. 4). Analogous to the con-
tribution of the SNS to leptin-mediated stimulation of UCP1
in BAT, the same mechanism might be expected to occur in
WAT, muscle and the liver. Data are emerging showing that
thyroid hormone secretion might be an additional mechanism
through which leptin affects UCP activity (31).
CNS targets of leptin involved in the regulation of adiposity
Several studies indicate that leptin mediates its effect on food
intake through modulatory actions on the synthesis of a
number of neuropeptides produced by neuronal cell bodies in
the base of the hypothalamus (including the Arc). One leptin-
binding neuronal cell type synthesizes neuropeptide Y (NPY)
and agouti-related protein (AgRP). NPY and AgRP are
potent stimulants of food intake and promote body weight
gain when administered into the CNS, while reduced leptin
signalling (e.g. in fasting or leptin-deficient rodents) consis-
tently upregulates NPY and AgRP mRNA in Arc neurones.
This upregulation of NPY and AgRP mRNA can be reversed
by i3vt administration of leptin. Another leptin-receptive cell
type cosynthesizes cocaine-amphetamine related transcript
(CART) and pro-opiomelanocortin (POMC), from which
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a-melanocyte stimulating hormone (aMSH) is cleaved. While
CART and aMSH reduce food intake and promote loss of
adiposity upon i3vt administration, leptin consistently up-
regulates the synthesis of these neuropeptides in fasting or
leptin-deficient rodents (8, 11, 13). The neuronal cell bodies
that produce NPY/AgRP and CART/POMC project intra-
hypothalamically as well as extra-hypothalamically (13) and
may affect food intake directly through changing the sen-
sation of hunger and/or satiety. Alternatively, they might
affect hunger/satiety feelings indirectly by altering the activ-
ity of classic neurotransmitter systems (e.g. that contain
norepinephrine, dopamine, serotonin and GABA) and/or
neuropeptide systems that contain for instance melanin-
concentrating hormone (32) and corticotropin releasing
hormone (CRH) (33, 34). Many of these hypothalamic
neuropeptidergic systems have been included in mediating
leptin effects on adiposity independent of their effects on
food intake. The most extensively studied ones are NPY,
POMC and CRH.
NPY
The first described neuropeptide with potent effects on energy
balance independent of food intake is NPY (35). NPY and
its receptors are abundantly expressed throughout the CNS.
Most relevant to regulation of energy balance are NPY-
containing neuronal cell bodies in the Arc that project
heavily to the PVN (36). When injected into the PVN of rats,
NPY reduces energy expenditure (37) and shifts the auto-
nonomic balance more towards parasympathetic activity (38);
the latter particularly occurring during food intake (38).
Consistent with its metabolic and autonomic effects are
findings by Zarzjevski et al. (39) demonstrating that, relative
to controls, chronic NPY administration into the lateral
cerebral ventricle produces hyperinsulinemia and increased
lipogenesis in rats in which their hyperphagia is prevented by
pair-feeding to controls. Besides affecting fuel partitioning
and metabolism, centrally administered NPY reduces sympa-
thetic outflow to BAT, thereby probably limiting its thermo-
genic capacity (40). The defective thermogenic response in
fatty Zucker rats is believed to be caused, in part, by a failure
to attenuate NPY transmission at the level of the hypo-
thalamus (41). The latter impairment is probably a direct result
of ablation of leptin action in the fatty Zucker rat (42).
Although studies in leptin-deficient or fasting rodents
clearly demonstrate that leptin reduces NPY synthesis and
transmission (43), it is not clear whether the interaction of
leptin with NPY synthesis in the Arc of genetically normal,
nonfasting rats is of major importance for the day-to-day
regulation of energy balance. For example, while food res-
triction of genetically normal rats clearly increases NPY
mRNA levels in the Arc nucleus of these animals (as can be
observed in rats that are pair-fed to match the reduced food
intake in i3vt leptin-treated animals [19]), i3vt leptin treatment
is not able to reverse the increased level of NPY mRNA to the
level of ad libitum controls (19). In contrast, i3vt leptin
treatment did significantly increase POMC and CRH mRNA
in the same animals compared to that of pair-fed controls (19).
These data might suggest that the interaction of leptin with
hypothalamic POMC and CRH synthesis, rather than with
NPY synthesis, is more relevant to the day to day regulation
of energy balance in genetically ‘normal’ rats. Of course, it
remains possible that leptin can influence the secretion of
NPY from nerve terminals without detectable changes in the
synthesis of NPY.
POMC
aMSH is one of several cleavage products of POMC, and may
be the most relevant for regulation of energy balance relative
to the other products. It acts as an agonist on brain melano-
cortin (MC) receptors (44), and competes with AgRP, which
acts as an endogenous antagonist on MC receptors (45). This
system has received much attention over the last few years
since obesity can occur from different mutations in the MC
pathway in humans (46). In addition, mice with a targeted
deletion in the gene encoding for the MC4 receptor become
morbidly obese (47). The MC4 receptor is widely expressed in
the brain and is found in the cortex, hippocampus, thalamus,
hypothalamus, spinal cord and peripheral sympathetic
nervous system (13). In the hypothalamus, MC4 receptors
are highly expressed in neuronal cell bodies of the DMH,
PVN and lateral hypothalamus, which all receive input from
arcuate hypothalamic neurones that produce aMSH and
AgRP (48). In addition to these intrahypothalamic projec-
tions, these neurones also project to regions outside the
hypothalamus, such as the intermediolateral cell column of
the spinal cord, which contains preganglionic motor neurones
of the sympathetic nervous system (13).
There are several lines of evidence demonstrating the
involvement of the brain MC system in leptin action. The first





















FIG. 4. Twenty-four hour core temperature patterns of ad libitum feeding
male Wistar rats averaged over three-hour periods (assessed with
DATAQUEST biotelemtry system) at the seventh day of chronic third-
cerebroventricular infusion (via osmotic minipumps; Alzet, model 2002)
with synthetic cerebrospinal fluid (sCSF; n=6) or leptin (10 mg/day,
n=5). At this particular day of treatment, the animals infused with leptin
consumed 52% of the amount eaten by sCSF-treated controls. The black
bar on the horizontal axis denotes the dark period. (de Vries et al., in
preparation).
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following an acute i3vt injection of leptin was prevented by
coadministration of the MC-R3/4 receptor antagonist,
SHU9119 (Ac-Nle4-c[Asp-His-D-Nal(2k)-Arg-Trp-Lys-NH2,
0.5 nmol), in a dose which was ineffective by itself to alter
food intake, when given i3vt acutely (49). Satoh et al. showed
that central SHU9119 treatment was also able to block the
effect of leptin of increasing UCP1 synthesis in BAT (50).
There is currently no data to show whether SHU9119 is able
to block the effect of leptin on UCP2 and UCP3. Nevertheless,
Haynes et al. found that the central stimulatory effects
of leptin on regional sympathetic nerve traffic in some, but
not all, tissues tested could at least partially be blocked
by SHU9119 pretreatment (51). The latter two observa-
tions indicate that MC receptors are directly involved in
mediating the metabolic effects of leptin.
In a recently published follow-up experiment, we
investigated the effect of chronic i3vt administration of
SHU9119 (0.5 nmol/day) during an 11-day period on food
intake, body weight and temperature regulation in rats (52).
Whereas acute i3vt injection of 0.5 nmol SHU9119 did not
affect food intake itself but was able to block the anorexigenic
effect of leptin (49), i3vt SHU9119 given chronically (by
osmotic minipumps) caused rats to slowly increase their food
intake to finally almost double the amount at the end of
treatment relative to sCSF-treated/ad libitum-fed controls. As
a consequence, there was a marked increase in body weight
and body fat content and a six-fold increase in the plasma
leptin level compared to those of controls (52). These data are
consistent with other studies investigating food intake and
body weight effects of chronic centrally administered receptor
antagonists (53). Furthermore, i3vt SHU9119-treated rats
in our study had a reduction in body temperature relative
to controls, and this effect was even more pronounced in
the SHU9119-treated animals that were pair-fed to con-
trols (Fig. 5).
The effects of i3vt SHU9119 treatment to reduce body
temperature were particularly pronounced during the dark
(i.e. active) phase; i.e. at the time when also the most dramatic
increases in food intake were observed in SHU9119-treated/ad
libitum feeding animals. The observation that the SHU9119-
treated/pair-fed animals had significantly more body fat and
a two-fold increase in the concentration of plasma leptin
compared to those of sCSF-treated controls is probably the
result of reduced thermogenesis, which is an indirect measure-
ment of metabolic rate (52). These data are consistent with a
recent study of Ste Marie et al., showing that wild-type mice
are leaner than MC4 receptor knockout mice that were pair-
fed to the wild-type mice (54). Taken together, these data
indicate that inhibition of MC receptor activity reduces brain
leptin effects on thermogenesis and metabolic rate. The notion
that leptin activates MC circuitry has been proven to be
correct via electrophysiological recordings of POMC neu-
rones, which were identified by targeted expression of green
fluorescent protein in transgenic mice (55).
CRH
CRH is produced in PVN neurones that project to several
brain regions, including the median eminence to regulate
ACTH secretion, and to the spinal cord to activate
sympathetic nervous system outflow (56). Important evidence
for involvement of CRH transmission in leptin action on food
intake has been provided in two separate studies by Uehara
et al. (33) and Gardner et al. (34). Both studies employed CRH
receptor antagonists to block leptin effects on food intake,
analogous to our study in which we were able to block leptin
effects on food intake with SHU9119 (49). Although PVN
neurones have remarkably low expression levels of Ob-Rb
mRNA, it has been shown in a number of studies that i3vt
leptin administration increases CRH mRNA in the parvo-
cellular PVN neurones (8, 19). This might suggest that other
leptin-receptive circuitry is required for activation of CRH-
containing PVN neurones. There is indeed evidence that MC
receptors, possibly via modulatory effects of interneurones,
can affect the activity of PVN neurones (57). Linkage between
leptin signalling through MC circuitry and activation of PVN
neurones is shown by our finding that i3vt SHU9119 admini-
stration is able to blunt the leptin-induced c-Fos labelling
of neurones in the PVN (49). At present, reports on direct
linkage between leptin signalling through MC receptors and
activation of PVN CRH neurones are not available. However,
we recently observed that i3vt administration of leptin (3.0 mg)
and the synthetic MC-R3/4 receptor agonist, melanotan II
(Ac-Nle4-c[Asp5, D-Phe7, Lys10]aMSH-(4-10)-NH2, 0.5 nmol)
equated to produce similar reductions in food intake caused
similar c-Fos labelling, in approximately 70% of the PVN
neurones that colabel CRH (van Dijk et al., unpublished























FIG. 5. Twenty-four hour core temperature patterns of ad libitum
feeding male Wistar rats averaged over three-hour periods (assessed
with DATAQUEST biotelemtry system) at the seventh day of chronic
third-cerebroventricular infusion (via osmotic minipumps; Alzet, model
2002) with synthetic cerebrospinal fluid (sCSF, n=6) or SHU9119
(0.5 nmol/day, n=7). At this day and particularly during the dark
phase, SHU9119-treated/ad libitum feeding animals ate 72% more than
the amount of food consumed by sCSF-treated controls. A third group
of animals was infused with SHU9119 but was pair-fed to the sCSF-
treated ad libitum control group (SHU9119/pair-fed). The black bar on
the horizontal axis denotes the dark period. Adapted from (52) with
permission.
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that the MC system serves a pivotal role in linking leptin
signalling to activation of CRH neurones.
Since injection of CRH into the cerebral ventricular system
stimulates thermogenesis and oxygen consumption and
potently reduces food intake and body weight (58, 59), it
can be suggested that activation of the melanocortin-CRH
loop is an important system to promote body weight loss. In
this respect, the trans-synaptic tracer studies by Bamshad et al.
[which showed some of the strongest labelling in the
parvocellular division of the PVN when the pseudorabies
tracer was injected in WAT or BAT (21)] are of interest.
Although the true identity of these peripherally projecting
PVN neurones remains to be investigated, it is very possible
that these parvocellular neurones contain CRH.
Conclusions and perspectives
Leptin has a major role in regulating energy balance
via modulatory actions on hypothalamic neuropeptide-
containing circuitry. In addition to the direct anorexigenic
effects elicited by leptin action on this circuitry, the reviewed
experiments demonstrate that increased central leptin signal-
ling stimulates food intake-independent mechanisms that
promote weight loss. These include an increase in energy
expenditure, thermogenesis and (at least in some tissues)
in-place degradation of triglyceride stores. In particular, CRH
produced in paraventricular hypothalamic neuronal cell
bodies might be important in mediating the central anorexi-
genic and catabolic effects of leptin, the latter presumably via
activation of sympathetic outflow to BAT, WAT, liver and
muscle. The brain MC system may provide a pivotal link
between CNS leptin signalling and activation of CRH
neurones. Disturbances in this link (e.g. receptor polymorph-
isms, receptor downregulation) may be a major contributor
to human obesity.
Among the many factors capable of reducing food intake
is an increase in the hepatic oxidation of fuels, including fat
fuels (60) and an increase in body temperature (61). The fact
that increased central leptin signalling increases fuel oxidation
and increases body temperature gives the rise to the possibility
that these metabolic and thermogenic effects induced by leptin
action in the CNS could elicit anorexigenic actions by them-
selves. According to the theory of thermoregulatory control
of food intake (29), it would be predicted that a thermogenic
compound would cause rats to eat smaller meals, and this is
exactly what i3vt leptin infused rats do (62). Thus, as shown
in Fig. 6, the peripheral effects mediated centrally by leptin,
in concert with changes in hypothalamic effector pathways
that act directly to inhibit food intake, are hypothesized to sus-
tain the negative energy balance and depletion of triglyceride
stores characteristic of leptin actions in the brain.
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